Abstract
Subcutaneous immunotherapy is a well documented treatment of allergic rhinitis and asthma. The majority of the disadvantages of the treatment are related to the poor quality of the natural allergen extracts which can contain varying amounts of individual allergens including allergens to which the patient may not be sensitized. Recombinant allergens offer a possibility to use well defined molecules with consistent pharmaceutical quality defined in mass units. The proof of concept of the clinical efficacy of recombinant allergens is based on two studies published as full articles.
| Original language | English |
|---|---|
| Journal | Current Opinion in Allergy and Clinical Immunology |
| Volume | 10 |
| Issue number | 6 |
| Pages (from-to) | 575-81 |
| Number of pages | 7 |
| ISSN | 1528-4050 |
| DOIs | |
| Publication status | Published - 1 Dec 2010 |
Fingerprint
Dive into the research topics of 'The current state of recombinant allergens for immunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS